Stockscreener 앱 받기
25.07
2.52%
0.76
전일 마감가:
$24.31
열려 있는:
$24.35
하루 거래량:
97,276
Relative Volume:
0.51
시가총액:
$442.84M
수익:
$116.88M
순이익/손실:
$-25.09M
주가수익비율:
-113.95
EPS:
-0.22
순현금흐름:
$-20.74M
1주 성능:
-9.24%
1개월 성능:
+68.28%
6개월 성능:
+172.67%
1년 성능:
+175.69%
1일 변동 폭
$23.74
$25.37
1주일 범위
$22.33
$27.82
52주 변동 폭
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RIGL | 25.05 | 442.84M | 116.88M | -25.09M | -20.74M | -0.22 |
| VRTX | 450.00 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28% - MSN
Rigel Pharmaceuticals To Present At Jefferies London Healthcare Conference; Webcast At 4:30 AM ET - Nasdaq
(RIGL) Proactive Strategies - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Reduces Stake in Rigel Pharmaceuticals Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $33.38 Average PT from Analysts - MarketBeat
Rigel Pharmaceuticals price target raised to $23 from $15 at Piper Sandler - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.00 at Piper Sandler - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia
Rigel Pharmaceuticals price target raised to $49 from $40 at Citi - TipRanks
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges - Investing.com
Rigel to Present at the Jefferies London Healthcare Conference - Yahoo Canada Finance
Citi raises Rigel Pharma stock target, buy rating on strong Gavreto sales - Investing.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Rigel stock rallies 36% after Q3 earnings beat - MSN
Rigel Pharmaceuticals stock hits 52-week high at $17.5 By Investing.com - Investing.com Australia
Earnings call: Rigel Pharmaceuticals reports strong Q3 growth, plans expansion - Investing.com Canada
Invesco Ltd. Bolsters Portfolio with Strategic Acquisition of Ri - GuruFocus.com
Rigel Pharmaceuticals stock hits 52-week high at $17.5 - Investing.com
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate - Simply Wall St
Rigel: Q3 Earnings Snapshot - Houston Chronicle
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlight - GuruFocus.com
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance Australia
Rigel Pharmaceuticals reports Q3 EPS 70c, consensus 6c - TipRanks
Rigel Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Rigel Pharmaceuticals (RIGL) Q3 2024 Earnings: EPS of $0.71, Rev - GuruFocus.com
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Report Preview: What To Expect - GuruFocus.com
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition - PR Newswire
Rigel's R289 Shows 36% Success in MDS Trial; Key Data Coming at ASH Meeting | RIGL Stock News - StockTitan
Certain Stock Options of Rigel Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-JAN-2018. - Marketscreener.com
Rigel Pharmaceuticals (RIGL) Scheduled to Post Earnings on Thursday - MarketBeat
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update - Quantisnow
441,765 Shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Bought by Assenagon Asset Management S.A. - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Up 54.9% in October - MarketBeat
Where are the Opportunities in (RIGL) - Stock Traders Daily
Rigel alerts healthcare providers of GAVRETO safety signal By Investing.com - Investing.com Australia
Rigel Pharmaceuticals (NASDAQ:RIGL) Earns Buy Rating from HC Wainwright - MarketBeat
Rigel issues letter to doctors on fatal infection signal for Gavreto - MSN
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):